| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Allovir, Inc. | Director | Common Stock | 504,000 | $5,078,203 | $10.08 | 18 Mar 2025 | Direct |
| Kalaris Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 18,000 | 10 Apr 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| KLRS | Kalaris Therapeutics, Inc. | 10 Apr 2025 | 1 | $0 | 4 | Director | 11 Apr 2025, 17:03 |
| KLRS | Kalaris Therapeutics, Inc. | 18 Mar 2025 | 1 | $0 | 4 | Director | 18 Mar 2025, 17:45 |
| KLRS | Kalaris Therapeutics, Inc. | 18 Mar 2025 | 0 | $0 | 3 | Director | 18 Mar 2025, 17:27 |